Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers
The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody–Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each p...
I tiakina i:
| Hōputu: | Online |
|---|---|
| Reo: | Ingarihi |
| I whakaputaina: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Ngā marau: | |
| Urunga tuihono: | ONIX_20220224_9783036526867_101 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
| _version_ | 1869518662223790080 |
|---|---|
| collection | Directory of Open Access Books |
| description | The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody–Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each paper was written by leading active research groups in their fields both from academia and industry. The book should be of interest to those scientists and researchers who develop or use biologics, biotherapeutics, biosimilars and biobetters in cancer treatment. |
| format | Online |
| id | doab-20.500.12854ir-78803 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-788032024-03-31T13:10:23Z Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers Kayser, Veysel monoclonal antibody NSCLC immunotherapy ELISA pharmacokinetics pharmacogenetics anti-PD-1 monoclonal antibodies anti-acetylcholine receptor (AChR) antibody B cell immune checkpoint blockade immune-related adverse events (irAEs) myasthenia gravis (MG) non-small-cell lung cancer (NSCLC) nivolumab programmed cell death ligand 1 (PD-L1) T cell tetraspanins cancer Tspan8 radioimmunotherapy immune-checkpoint inhibitors LDH biomarkers Ang-2 antiangiogenic therapy in vivo imaging radio- and chemotherapy VEGF-A cancer therapy neovascularization angiogenesis tumor microenvironment colorectal cancer antibody NK cells ADCC CD133 prominin-1 gold nanoparticles antibody-drug conjugates cell penetrating peptide HIV-1 TAT active-targeting targeted delivery trastuzumab MMAE valine-citrulline affibody drug conjugates hepatic uptake DM1 dermatooncology immune checkpoints monoclonal antibodies passive immunotherapy canine B-cell lymphoma DLA-DR HLA-DR antibody-drug conjugate ADC methotrexate tumor immunity combination therapy multiple myeloma (MM) monoclonal antibodies (mAbs) antibody products B cell maturation antigens (BCMAs) bispecific T cell engagers (BiTEs®) checkpoint inhibitors 1 protein structure 2 pharmacokinetics 3 drug optimization 4 HER2-positive breast cancer metastatic disease neoadjuvant and adjuvant therapy targeted therapy acute myeloid leukemia CD123 IL3RA kinesin spindle protein inhibitor thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody–Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each paper was written by leading active research groups in their fields both from academia and industry. The book should be of interest to those scientists and researchers who develop or use biologics, biotherapeutics, biosimilars and biobetters in cancer treatment. 2022-02-24T10:37:03Z 2022-02-24T10:37:03Z 2022 book ONIX_20220224_9783036526867_101 9783036526867 9783036526874 https://directory.doabooks.org/handle/20.500.12854/78803 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4898 https://mdpi.com/books/pdfview/book/4898 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-2686-7 10.3390/books978-3-0365-2686-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036526867 9783036526874 298 Basel open access |
| spellingShingle | monoclonal antibody NSCLC immunotherapy ELISA pharmacokinetics pharmacogenetics anti-PD-1 monoclonal antibodies anti-acetylcholine receptor (AChR) antibody B cell immune checkpoint blockade immune-related adverse events (irAEs) myasthenia gravis (MG) non-small-cell lung cancer (NSCLC) nivolumab programmed cell death ligand 1 (PD-L1) T cell tetraspanins cancer Tspan8 radioimmunotherapy immune-checkpoint inhibitors LDH biomarkers Ang-2 antiangiogenic therapy in vivo imaging radio- and chemotherapy VEGF-A cancer therapy neovascularization angiogenesis tumor microenvironment colorectal cancer antibody NK cells ADCC CD133 prominin-1 gold nanoparticles antibody-drug conjugates cell penetrating peptide HIV-1 TAT active-targeting targeted delivery trastuzumab MMAE valine-citrulline affibody drug conjugates hepatic uptake DM1 dermatooncology immune checkpoints monoclonal antibodies passive immunotherapy canine B-cell lymphoma DLA-DR HLA-DR antibody-drug conjugate ADC methotrexate tumor immunity combination therapy multiple myeloma (MM) monoclonal antibodies (mAbs) antibody products B cell maturation antigens (BCMAs) bispecific T cell engagers (BiTEs®) checkpoint inhibitors 1 protein structure 2 pharmacokinetics 3 drug optimization 4 HER2-positive breast cancer metastatic disease neoadjuvant and adjuvant therapy targeted therapy acute myeloid leukemia CD123 IL3RA kinesin spindle protein inhibitor thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers |
| title | Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers |
| title_full | Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers |
| title_fullStr | Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers |
| title_full_unstemmed | Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers |
| title_short | Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers |
| title_sort | therapeutic monoclonal antibodies and antibody products their optimization and drug design in cancers |
| topic | monoclonal antibody NSCLC immunotherapy ELISA pharmacokinetics pharmacogenetics anti-PD-1 monoclonal antibodies anti-acetylcholine receptor (AChR) antibody B cell immune checkpoint blockade immune-related adverse events (irAEs) myasthenia gravis (MG) non-small-cell lung cancer (NSCLC) nivolumab programmed cell death ligand 1 (PD-L1) T cell tetraspanins cancer Tspan8 radioimmunotherapy immune-checkpoint inhibitors LDH biomarkers Ang-2 antiangiogenic therapy in vivo imaging radio- and chemotherapy VEGF-A cancer therapy neovascularization angiogenesis tumor microenvironment colorectal cancer antibody NK cells ADCC CD133 prominin-1 gold nanoparticles antibody-drug conjugates cell penetrating peptide HIV-1 TAT active-targeting targeted delivery trastuzumab MMAE valine-citrulline affibody drug conjugates hepatic uptake DM1 dermatooncology immune checkpoints monoclonal antibodies passive immunotherapy canine B-cell lymphoma DLA-DR HLA-DR antibody-drug conjugate ADC methotrexate tumor immunity combination therapy multiple myeloma (MM) monoclonal antibodies (mAbs) antibody products B cell maturation antigens (BCMAs) bispecific T cell engagers (BiTEs®) checkpoint inhibitors 1 protein structure 2 pharmacokinetics 3 drug optimization 4 HER2-positive breast cancer metastatic disease neoadjuvant and adjuvant therapy targeted therapy acute myeloid leukemia CD123 IL3RA kinesin spindle protein inhibitor thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries |
| topic_facet | monoclonal antibody NSCLC immunotherapy ELISA pharmacokinetics pharmacogenetics anti-PD-1 monoclonal antibodies anti-acetylcholine receptor (AChR) antibody B cell immune checkpoint blockade immune-related adverse events (irAEs) myasthenia gravis (MG) non-small-cell lung cancer (NSCLC) nivolumab programmed cell death ligand 1 (PD-L1) T cell tetraspanins cancer Tspan8 radioimmunotherapy immune-checkpoint inhibitors LDH biomarkers Ang-2 antiangiogenic therapy in vivo imaging radio- and chemotherapy VEGF-A cancer therapy neovascularization angiogenesis tumor microenvironment colorectal cancer antibody NK cells ADCC CD133 prominin-1 gold nanoparticles antibody-drug conjugates cell penetrating peptide HIV-1 TAT active-targeting targeted delivery trastuzumab MMAE valine-citrulline affibody drug conjugates hepatic uptake DM1 dermatooncology immune checkpoints monoclonal antibodies passive immunotherapy canine B-cell lymphoma DLA-DR HLA-DR antibody-drug conjugate ADC methotrexate tumor immunity combination therapy multiple myeloma (MM) monoclonal antibodies (mAbs) antibody products B cell maturation antigens (BCMAs) bispecific T cell engagers (BiTEs®) checkpoint inhibitors 1 protein structure 2 pharmacokinetics 3 drug optimization 4 HER2-positive breast cancer metastatic disease neoadjuvant and adjuvant therapy targeted therapy acute myeloid leukemia CD123 IL3RA kinesin spindle protein inhibitor thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries |
| url | ONIX_20220224_9783036526867_101 |